- Home
- SB vs ORKA Comparison
SB vs ORKA Comparison
Compare SB & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- ORKA
- Stock Information
- Founded
- SB 2007
- ORKA 2004
- Country
- SB Monaco
- ORKA United States
- Employees
- SB N/A
- ORKA N/A
- Industry
- SB Marine Transportation
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SB Consumer Discretionary
- ORKA Health Care
- Exchange
- SB Nasdaq
- ORKA Nasdaq
- Market Cap
- SB 395.3M
- ORKA 393.1M
- IPO Year
- SB 2008
- ORKA N/A
- Fundamental
- Price
- SB $3.42
- ORKA $9.54
- Analyst Decision
- SB Strong Buy
- ORKA Strong Buy
- Analyst Count
- SB 1
- ORKA 7
- Target Price
- SB $6.00
- ORKA $39.67
- AVG Volume (30 Days)
- SB 389.4K
- ORKA 189.2K
- Earning Date
- SB 05-20-2025
- ORKA 05-19-2025
- Dividend Yield
- SB 5.87%
- ORKA N/A
- EPS Growth
- SB 36.11
- ORKA N/A
- EPS
- SB 0.83
- ORKA N/A
- Revenue
- SB $307,633,000.00
- ORKA N/A
- Revenue This Year
- SB N/A
- ORKA N/A
- Revenue Next Year
- SB $14.32
- ORKA N/A
- P/E Ratio
- SB $4.12
- ORKA N/A
- Revenue Growth
- SB 8.17
- ORKA N/A
- 52 Week Low
- SB $3.02
- ORKA $5.49
- 52 Week High
- SB $6.33
- ORKA $53.88
- Technical
- Relative Strength Index (RSI)
- SB 49.46
- ORKA N/A
- Support Level
- SB $3.33
- ORKA N/A
- Resistance Level
- SB $3.53
- ORKA N/A
- Average True Range (ATR)
- SB 0.09
- ORKA 0.00
- MACD
- SB 0.02
- ORKA 0.00
- Stochastic Oscillator
- SB 67.65
- ORKA 0.00
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.